CK Life Sciences (HKG:0775) expects to post a loss attributable to shareholders of about HK$150 million for the six months ended June 30, compared with a profit of HK$1 million a year prior, a Thursday Hong Kong bourse filing said.

Shares of the company were down about 5% in Friday's recent trade.

The anticipated loss was mainly due to a planned increase in R&D investment, though overall operations remained stable during the period.

The interim results will be published on Aug. 12.